Interleukin 18 (IL18) is known to induce the expression of interferon-γ (IFNG), but its effects on T 19 cell proliferation and costimulation are not completely understood. In this study, we 20 demonstrate that ectopic expression of IL18 in CART cells caused significant T cell proliferation 21 in vitro and in vivo, and enhanced antitumor effects in xenograft models. Moreover, IL18 22 mediated T cell expansion required neither tumor antigen nor CAR expression, and produced 23 severe GVHD in NSG mice. Furthermore, recombinant IL18 costimulated IFNG secretion and 24 proliferation of anti-CD3 beads treated T cells. Interestingly, IL18 costimulation could expand 25 purified CD4 T cells, but not CD8 T cells. However, CD8 T cells proliferated greater than CD4 T 26 cells in magnitude within bulk T cells, suggesting CD4 help effect was involved. Using 27 CRISPR/Cas9 gene editing, we confirmed that IL18-driven expansion was both TCR and IL18 28 receptor (IL18R) dependent. Importantly, we demonstrated that TCR-deficient, IL18-expressing 29 CD19 CART cells exhibited remarkable proliferation and persistent antitumor activity against 30 CD19-expressing tumor cells in vivo, without eliciting any detectable GVHD symptom. Finally, we 31 describe APACHE T cells, a novel strategy for coupling IL18 expression in CART cells to antigen 32 stimulation, thereby limiting potential toxicity associated with persistent IL18 production. In 33 sum, our study supports human IL18 as a T cell costimulatory cytokine for fueling CART therapy. 34 35
Introduction 51
Following the initial reports of clinical success using chimeric antigen receptor (CAR) T cell 52 therapy to treat B cell leukemia and lymphoma (Kochenderfer et al., 2010; Porter et al., 2011), 53 there have been intense efforts to improve the design and clinical translation of CART cells 54 (Dotti et al., 2014; Jensen and Riddell, 2014 ; Kalos and June, 2013) . It is well established that T 55 cell receptor (TCR) engagement and costimulatory signaling provide the critical signals that 56 regulate T cell activation, proliferation and cytolytic functions (Chen and Flies, 2013) . In addition 57
to TCR and costimulatory signals, exogenous cytokines also play a fundamental role in 58 modulating T cell function (Curtsinger and Mescher, 2010) , as reflected in the influence of 59 cytokines produced by CD4+ T helper cells on the activity of CD8+ cytotoxic T cells (Bevan, 2004) . 60 For example, interleukin 2 (IL2) promotes clonal expansion of effector T cells in response to 61 antigen stimulation, and is also required to maintain suppressive regulatory T (Treg) cell-62 mediated immune tolerance (Boyman and Sprent, 2012) . 63 CART cells are among the most promising of multiple adoptive T cell transfer-based 64 immunotherapies currently under development (Harris and Kranz, 2016; Hinrichs and Rosenberg, 65 2014; Lu et al., 2014; Robbins et al., 2013) . The manufacture of sufficient tumor-specific T cells 66 in a clinical setting has relied on the use of exogenous cytokines, including IL2, IL7 andIL15, to 67 promote ex vivo expansion of genetically engineered T cells (Cha et al., 2010; Cieri et al., 2013) . 68 In addition, IL21 has been shown to promote expansion and engraftment of adoptively 69 transferred T cells (Chapuis et al., 2013) . 70
Although many immune cytokines have been evaluated for their ability to promote anti-tumor 71 immunity when delivered exogenously (Dranoff, 2004 ; Lee and Margolin, 2011) , reports of 72 toxicity and/or lack of efficacy have limited their success. Several attempts to replace exogenous 73 cytokine treatment with T cell-autonomous cytokine production have been reported. For 74 example, tethering IL15 to CART cells was shown to enhance T cell persistence and antitumor 75 activity (Hurton et al., 2016) ; however, there are concerns that this approach could lead to 76 transformation of the T cells (Hsu et al., 2007; Sato et al., 2011) . Similarly, IL12-expressing T cells 77 have been investigated in multiple preclinical studies (Chinnasamy et and IL12-expressing tumor infiltrating lymphocytes (TIL) were recently used to treat melanoma 80 patients (Zhang et al., 2015) . Although IL12-expressing TIL therapy resulted in effective anti-81 tumor response, toxicity from persistent, elevated serum IL12 concentrations was observed. 82
More recently, interferon-β(IFNB) has shown efficacy in bridging innate and adaptive immune 83 responses (Yang et al., 2014) , and may be an attractive option for engineering cytokine 84 producing CART in future (Zhao et al., 2015) . 85
We hypothesized that including an IL18 gene expression cassette in the CAR lentiviral vector 86 might overcome the requirement for exogenous cytokine stimulation, and promote improved 87
antitumor CART cell effects. IL18 was initially characterized as an inducer of interferon-γ (IFNG) 88 expression in T cells (Nakamura et al., 1993; Nakamura et al., 1989) ,and was shown to activate 89 lymphocytes and monocytes, without eliciting severe dose limiting toxicity, in a previous clinical 90 study (Robertson et al., 2006) . The combination of IL18 with IL12 treatment promotes Th1 and  91 NK cell responses (Nakanishi et al., 2001) , but also induces lethal toxicity in murine models 92 (Carson et al., 2000; Osaki et al., 1998) , reflecting the dynamic tension between achieving high 93 potency and inducing toxicity in cytokine based immunotherapies. Despite initial indications that 94 IL18 treatment alone may be only minimally effective in boosting anti-tumor immunity (Osaki et  95 al., 1998), we previously reported that recombinant human IL18 could significantly enhance 96 engraftment of human CD8 T cells in a xenograft model (Carroll et al., 2008) . 97
In the current study, we demonstrate that T-cell autonomous IL18 expression, in combination 98
with CAR or TCR signaling, promotes significant T cell proliferation in vitro and in vivo. Moreover, 99
IL18 mediated T cell expansion in xenograft model required neither tumor antigen nor CAR 100 expression, and produced severe GVHD in NSG mice. Interestingly, CD4+ T cells expanded 101 preferentially in response to IL18 costimulation. Using CRISPR/Cas9 gene editing, we confirmed 102 that IL18-dependent T cell expansion was both TCR and IL18 receptor (IL18R) dependent. 103
Importantly, we demonstrated that TCR-deficient, IL18-expressing CD19 CART cells exhibited 104 remarkable proliferation and persistent antitumor activity against CD19-expressing tumor cells 105
and did not cause GVHD in vivo. These data support the redefinition of human IL18 as a T cell 106 costimulatory cytokine and the utility of engineering CART cells to express IL18. We further 107 describe an inducible expression system that couples IL18 expression levels to CAR stimulation, 108 thereby reducing potential toxic effects of persistent IL18 expression in the absence of tumor 109 antigen. Collectively, these studies identify a novel approach to enhancing CART cell expansion 110
in vivo, which is a critical determinant of successful CART cancer immunotherapy. 111 112 113
Results

114
IL18 enhances proliferation of polyclonal antigen-specific and non-specific CAR T cells in vivo 115
To test the hypothesis that elevated IL18 signaling can enhance the anti-tumor effects of CART 116 cell therapy, we introduced a gene expression cassette encoding human IL18 (or GFP as a 117 negative control) into a previously described anti-mesothelin (SS1) CAR lentiviral construct (SS1-118 IL18) ( Figure 1A) . Similarly, the IL18 gene cassette was introduced into an anti-CD19 CAR 119 construct (CD19-IL18) to serve as a control for antigen-specific effects ( Figure 1A ). SS1-IL18 CART 120 cells efficiently expressed SS1 CAR and secreted active human IL18 into the culture medium, as 121 assessed using an IL18 reporter cell line ( in vivo. AsPC1 cells expressing click beetle green (CBG) and GFP reporter proteins were injected 128 into NSG mice to generate xenograft tumors. Tumor-bearing mice were then injected with SS1, 129 SS1-IL18, CD19 or CD19-IL18 CART cells, and tumor burden was monitored by bioluminescence. 130
Surprisingly, both CD19-IL18 and SS1-IL18 CART cells suppressed tumor progression while 131 inducing significant loss of body weight ( Figure 1B) , and CD19-IL18 or SS1-IL18 T cells were 132 dramatically expanded 62-fold to 13993 cells/μl, or 74-fold to 38211 cells/μl, respectively 133 ( Figure 1C ). Moreover, the serum IL18 concentration was increased to 44291pg/ml in SS1-IL18 134
CART cells ( Figure 1C ). These results indicate that CART cell-autonomous IL18 expression can 135 drive expansion of both antigen-specific and non-specific CART cells in NSG mice. 136
To further analyze the specific effects of IL18 expression on CART cell proliferation, splenic T 137 cells were analyzed for CAR expression by flowcytometry. Interestingly, in mice receiving SS1 138
CART cells, 96.4% of the in vivo expanded CD8 T cells were CAR+, whereas only 50% of the CD8+ 139
T cells in mice receiving SS1-IL18 CART cells were CAR+ ( Figure 1D ,E). This expansion is more 140 favorable to SS1 CAR+ T cells, as only approximately 24% of the expanded human T cells were 141 CAR+ in mice receiving CD19-IL18 CART cells ( Figure 1D ,E). The percentage of CAR+ cells within 142
CD4 or CD8 subsets are summarized in Figure 1E . These results suggested that IL18 promotes 143 proliferation of both CAR+ and CAR-T cells in autocrine and paracrine modes. Phenotyping of 144
TCRβ (TCRB) variants on expanded T cells reveals that all CART cell groups exhibit polyclonal 145 expansion ( Figure 1 -figure supplement 2), suggesting that IL18 expression does not select for 146 particular TCR specificities. 147
IL18 mediated T cell proliferation induces lethal GVHD 148
Our observation that CD19-IL18 CART cells elicited antitumor activity and loss of body weight, as 149 well as the expansion of untransduced T cells in mice receiving IL18-CART cells, suggested that 150 IL18 expression in these contexts might promote severe GVHD, consistent with our previous 151 report (Carroll et al., 2008) . To test the severity of GVHD associated with IL18-CART cell therapy, 152
we injected tumor-free NSG mice with either SS1 or SS1-IL18 CART cells, and monitored 153 circulating human T cell levels, serum IL18 concentrations, body weight, and survival ( Figure 1F ). 154
As SS1-IL18 CART cells expanded, mice exhibited significant loss of body weight, and started to 155 die approximately 3 weeks after T cell injection ( Figure 1F ). Similarly, NSG mice bearing CD19-156
expressing Nalm6 tumors treated with CD19-IL18 CART showed dramatic expansion of human T 157 cells in blood and spleen ( Histological analyses confirmed that treatment with either SS1-IL18 and CD19-IL18 CART cells 162 induced significant tumor destruction ( Figure 1G ). Immunohistochemical analysis for CD3 163 expression revealed the presence of T cells in the tumor treated with IL18-CART ( Figure 1H ), and 164 necropsy of mice receiving SS1-IL18 CART cells (Table S1 ), revealed remarkable GVHD in liver 165 and lung and atypical lymphocyte infiltration in pancreas ( Figure 1I ). 166
Collectively, our results suggest that expressing IL18 in the context of CART cell therapy can 167 enhance antitumor effects and xenogeneic GVHD, but may also produce unwanted toxicity due 168
to TCR-mediated autoimmune effects in an autologous setting, or GVHD in an allogeneic setting. 169
To optimize the use of IL18 in CART cell therapy, it was therefore important to dissect the 170 contribution of TCR signaling to IL18-mediated CART cell effects in vitro and in vivo. 171
TCR activation and IL18 promotes CD4 helper dependent T cell expansion in vitro and in vivo 172
Based on our observation that IL18 expressing T cells proliferated in NSG mice independent of 173 CAR activation, and produced xenogeneic GVHD, we speculated that a functional synergy exists 174 between IL18 and TCR stimulation. To test this hypothesis in vitro, primary human T cells were 175 stimulated using anti-CD3 beads and recombinant IL18. Whereas combined exposure to anti-176 CD3 beads and IL18 efficiently stimulated increases in T cell size and proliferation (Figure 2A ,B), 177
neither treatment alone was effective, although anti-CD3 beads alone caused intermediate 178 increase in size without triggering T cell proliferation. These results were confirmed in T cells 179 isolated from two normal donors ( Figure 2C ). 180
To better characterize IL18 activation of T cells, we collected the culture supernatants at D5 181 from different conditions as indicated to analyze the profile of secreted cytokines. As expected, 182 low concentrations of IL18 combined with anti-CD3 beads, significantly enhanced IFNG 183 production compared to beads alone ( Figure 2D ). Although low concentrations of IL18 and anti-184 CD3 beads treatment enhanced IL2 production, maximal IL2 levels were at least 20-fold lower 185 than those induced by standard anti-CD3/28 beads ( Figure 2D ). The production of other 186 cytokines was generally comparable between CD3/IL18 and CD3/D28 activation ( GFP-IL18 expressing CD8 T cells also failed to expand in vivo following injection into NSG mice 201 ( Figure 2G ). In contrast, GFP-IL18 expressing CD4 or bulk T cells exhibited greater than 400-fold 202 expansion between days 15 to 23 post T cell injection ( Figure 2G ), and were associated with 203 enlarged spleens ( Figure 2H ). The number of expanded CD4 T cells was comparable whether 204 pure CD4 T cells or total T cells were injected, suggesting that CD8 T cells do not have a 205 significant effect on CD4 T cell expansion ( Figure 2I ). Interestingly, CD8 T cells proliferated 206 greater than CD4 T cells in magnitude within bulk T cells, suggesting CD4 help effect was 207 involved ( Figure 2J ). 208
Serum cytokine levels were determined in mice receiving CD4, CD8, or bulk T cells expressing 209 GFP-IL18, or control GFP T cells. Consistent with our in vitro results, serum IL18 levels increased 210
in the GFP-IL18 T cell and GFP-IL18 CD4 T cell populations, but not in the isolated GFP-IL18 CD8 T 211 cell population ( Figure 2K ). IFNG levels also increased in proportion to T cell expansion ( Figure  212 2L), and GM-CSF levels were significantly elevated in the expanding GFP-IL18 T cell and GFP-IL18 213
CD4 T cell populations, whereas other cytokines failed to show large changes ( Figure 2M ). In 214 summary, these results suggested that IL18 acts as a costimulatory cytokine that interacts 215 synergistically with TCR activation to drive efficient T cell proliferation, largely dependent on 216 effects through CD4 helper T cells. 217
CAR or TCR signaling is required for IL18 mediated T cell proliferation in vitro or in vivo 218
To first evaluate the effect of IL18 coexpression on CART cell proliferation in vitro, we deleted 219
TCR mediated allogeneic effect in SS1-IL18 and CD19-IL18 CART cells using CRISPR/Cas9 gene 220 editing as previously described (Ren et al., 2016) . TCR KO IL18-CART cells had only marginally 221 enhanced expansion following CD3/CD28 beads activation and RNA electroporation ( Figure 3A ). 222
When stimulated with irradiated K562 cells expressing cognate antigen and exogenous IL2, SS1-223 IL18 CART cells displayed significantly increased proliferation relative to SS1 CART cells ( Figure  224 3B), which were producing high level of IFNG and IL2, and polyclonal in TCRB variants 225 distribution ( supplement 3B). Collectively these data indicate that CAR or TCR activation is required for IL18-245 mediated T cell proliferation in vitro or in vivo, respectively. 246
IL18 receptor is required for cell-autonomous IL18-medated T cell expansion in vivo 247
To further investigate the synergy between IL18 and TCR signaling, we generated IL18Rα (IL18RA) 248 deficient T cells using CRISPR/Cas9 mediated gene editing (Figure 4-figure supplement 1A,B ). We 249 next employed a cell competition assay using four distinct populations of engineered T cells 250
( Figure 4A ). These included (1) WT CD19-IL18 T cells;
(2) WT GFP T cells;
(3) TCR KO T cells 251 labeled with DsRed; and (4) IL18R KO T cells labeled with AmCyan. Successful deletion of the TCR 252 and IL18R was confirmed by flowcytometry, and MACS depletion was performed to remove any 253 residual T cells expressing either TCR or IL18R proteins ( Figure 4B ). Following ex vivo expansion, 254
all four T cell populations were mixed and flowcytometry analysis confirmed the ratio of (WT 255 CD19-IL18):(WT GFP):(TCR KO DSRED):(IL18R KO AMCYAN) cells to be 8.59% : 7.45% : 6.71% : 256
7.27% of total T cells ( Figure 4C ). The mixed population of T cells was injected into NSG mice and 257 blood and spleen were collected for analysis when mice exhibited significant loss of bodyweight. 258
Staining for IL18RA indicated that AmCyan labeled T cells partially regained low levels of IL18R 259 expression ( Figure 4D ), and likely represent T cells that did not undergo successful gene editing 260
and were not completely removed by MACS depletion. 261
Flowcytomety analysis revealed the final ratio of (WT CD19-IL18):(WT GFP):(TCR KO 262 DSRED):(IL18R KO AMCYAN) to be 22.0% : 18.0% : 5.82% : 0.43% ( Figure 4E ). The number of 263 CD45+ human T cells in individual mice ranged from 32800 to 79600 cells/μl blood ( Figure 4F ), 264
confirming that all mice exhibited IL18-mediated T cell proliferation. Interestingly, the ratio of 265 WT CD19-IL18 to WT GFP T cells following in vivo expansion was essentially unchanged ( Figure  266 4G), consistent with the data in Figure 1D ,E indicating that IL18 could drive equal expansion of 267 CD19 CAR positive and negative T cells. In contrast, the proportion of IL18R KO AMCYAN T cells 268 decreased significantly in blood and spleen, and it was even more dramatic for TCR KO DSRED T 269 cells ( Figure 4G ). These data indicate that both TCR and IL18R signaling are required for IL18 270 mediated proliferation of human T cells as tested in vivo in the NSG model. 271
IL18 costimulation with CAR signaling significantly enhanced CART proliferation and antitumor 272 activity in xenograft model 273
As our data indicate that IL18 expression promotes TCR-mediated T cell proliferation, we 274
hypothesized that IL18 costimulation would also enhance CART cell proliferation and anti-tumor 275 efficacy. To avoid GVHD, only TCR-deficient (TCR-) T cells were used in these experiments. NSG 276 mice were engrafted with Nalm6 tumor cells expressing CBG and GFP reporter proteins, and 277 subsequently treated with either TCR-CD19-IL18 or control TCR-CD19-GFP CART cells. Tumor 278 burden was assessed by bioluminescent imaging. TCR-CD19-IL18 T cells effectively cleared 279 detectable tumor cells by day 10 ( Figure 5A) , in contrast to TCR-CD19-GFP T cells ( Figure 5A,B) . 280
In addition, TCR-SS1-IL18 CART cells had no effect on tumor progression ( Figure 5B ). Although 281 TCR-CD19-IL18 CART cells caused a transient decrease in body weight at D8, body weight 282 returned to baseline levels and remained stable thereafter ( Figure 5C ). Remarkably, mice  283  injected with TCR-CD19-IL18 CART cells remained viable for over 185 days post T cell injection,  284 except for one mouse that exhibited tumor relapse at day 101 ( Figure 5A ,D) due to 285 downregulation of CD19 expression ( Figure 5-figure supplement 1A) . Emergence of 286
contaminating TCR+ CD19-IL18 CART cells was not observed at any point during treatment 287 ( Figure 5G ). 288
From day 10 through day 21, mice receiving TCR-CD19-IL18 CART cells maintained 289 approximately 350 CD3-CD45+ T cells/μl blood ( Figure 5E ), whereas the number of CD19-GFP 290
CART cells varied between0.8 and 10.5 CD3-CD45+ T cells/μl. This approximately 100-fold 291 difference suggests that IL18 significantly enhanced of proliferation CD19 CART cells, resulting in 292 superior antitumor activity. Consistent with the expansion of CD19 CART cells, IL18 293 concentrations were high, averaging 77500pg/ml at D10 ( Figure 5F ). Subsequently, the number 294 of T cells and IL18 concentrations decreased to below 1 CD3-CD45+ T cell/μl and approximately 295 100pg/ml in tumor-free mice. Flowcytometric analyses revealed that the distribution of CD4 and 296 CD8 T cells rapidly evolved from equal balance at D10 (37% vs 55%, respectively) to CD4 297 domination at D21 (86% vs 11%) ( Figure 5H ). Interestingly, CD19-IL18 CART cells attained a 298 primarily EM phenotype in both CD4 and CD8 subsets ( Figure 5I ). In the single mouse that 299 developed a recurrent tumor associated with CD19 downregulation ( These results collectively demonstrate that IL18 can significantly enhance CART cell proliferation 306 and induce superior anti-tumor activity. Equally important, the use of TCR-deficient CART cells 307 obviated concerns of developing TCR-mediated GVHD during therapy. 308
Designing an NFAT-based inducible system for IL18 production: APACHE T cells 309
Our data indicate that including the IL18 expression cassette within the CAR lentiviral design 310 strongly enhanced T cell proliferation in response to TCR or CAR stimulation, and may be 311 preferable to expanding CART cells that do not constitutively secrete cytokines. However, the 312 high concentration of systemic IL18 produced by CART cells could raise potential safety concerns 313 related to pathological activation or proliferation of bystander T cells reacting against foreign or 314 self-antigens, or induction of NK cell mediated inflammation. We therefore designed an 315
inducible system in which IL18 production is only activated after CAR engagement with tumor 316
antigen. Specifically, we generated a lentiviral vector in which the expression of CD19 CAR, GFP, 317 and IL18 is under the control of the NFAT promoter ( Figure 6A ). Once expressed, CD19 CAR will 318 engage with antigen to stimulate NFAT promoter activity. This, in turn, will maintain CD19 CAR 319 and IL18 expression through a positive feedback circuit. Once tumor antigen is cleared, CD19 320 CAR and IL18 expression levels should return to baseline, overcoming potential toxic effects of 321 long-term constitutive IL18 expression. Because the endogenous TCR can also activate NFAT 322 signaling pathways, we conducted these experiments in T cells rendered deficient in TCR 323 expression by CRISPR/Cas9. In order to initially activate the signaling cascade, the cells were 324 engineered to transiently express a CD19 CAR by mRNA electroporation into TCR-deficient T 325 cells already lentivirally transduced with the NFAT-driven cassette (Ren et al., 2016; Zhao et al., 326 2010), as shown in Figure 6A . Deleting the TCR gene in these cells by CRISPR/Cas9 gene editing 327 avoids unwanted NFAT activation by endogenous TCR signaling ( Figure 6A ). 328
We tested the inducible NFAT-CD19-GFP-IL18 TCR-deficient T cells expanded as described in the 329 timeline shown in Figure 6A . TCR-/NFAT-CD19-GFP-IL18 T cells were restimulated under 330 different conditions, and analyzed for GFP expression and IL18 production. The results showed 331 that irradiated K562-CD19 aAPC and PMA/ionomycin treatment induced similar levels of GFP 332 expression and IL18 synthesis in TCR WT and TCR KO NFAT-CD19-GFP-IL18 T cells, whereas anti-333 CD3/28 beads only activated GFP expression and IL18 synthesis in TCR WT NFAT-CD19-GFP-IL18 334 T cells ( Figure 6B,C) .This observation demonstrated that the inducible system, which we 335
deemed Antigen Propelled Activation of Cytokine Helper Ensemble (APACHE), operates as 336
intended. In NSG mice bearing Nalm6 xenograft tumors, APACHE-armored CD19 CART cells 337 suppressed tumor progression more effectively, and resulted in better survival, than TCR-/NFAT 338 CD19-GFP CART cells and TCR-/untransduced (UTD) T cells expressing mRNA encoded CD19 CAR 339
( Figure 6D,E) . APACHE-armored CD19 CART cells did not induce significant loss of body weight 340 and only low levels of systemic IL18 were detected at day 10 and day 15 following T cell 341 injection ( Figure 6E ), suggesting that this inducible system could minimize the potential risk of 342 continuous systemic IL18 expression. IL18, including that it is a single chain cytokine in contrast to IL12, which is heterodimeric. In 352
addition, IL18 has been tested as a single agent in clinical trials and shown to have moderate 353 antitumor effects and an acceptable safety profile (Robertson et al., 2006) . In contrast, IL12 has 354 been shown to have unacceptable toxicity in previous trials (Cohen, 1995) . 355
IL18 can regulate both innate and adaptive immune responses through its effects on natural 356 killer (NK) cells, monocytes, dendritic cells, T cells, and B cells (Dinarello et al., 2013). The most 357
important biologic effect of IL18 is that it acts synergistically with other pro-inflammatory 358 cytokines to promote interferon-γ production by NK cells, T cells, and possibly other cell types. 359 Due to the pleiotropic functions of IL18, tissue-accumulated IL18 has been shown to impact both 360 the tumor stroma and the immune response, by sustaining T cell cytolytic activity, recruiting and 361 activating innate immune cells, and re-programming stroma associated immune suppressor cells 362 (Chmielewski et al., 2014) . The rationale for our studies is that the accumulation of IL18 as a 363 transgenic pro-inflammatory cytokine is intended to recruit a second wave of immune cells to 364 the tumor microenvironment to mediate antitumor effects towards cancer cells that are 365 resistant to the direct effects of the CAR T cells. 366
Many studies have shown that efficacy of adoptive cell therapy with tumor targeted T cells is 367 enhanced by host conditioning using radiation or lymphodepleting chemotherapy. Intensive 368 chemotherapy or radiation given to enhance adoptive cell therapy has been reported to have 369 severe toxicity in some patients (Goff et al., 2016) . Given the pronounced augmentation of CAR 370 T cell engraftment that we observed with T cells secreting IL18, it is possible that this may 371 decrease the need for prior host conditioning. In preclinical models with mouse CAR T cells 372 engineered to secrete IL-12, the need for lymphodepletion was obviated (Pegram et al., 2012) . 373
One concern with CAR T cells armored with IL18 is the potential for systemic inflammation (Car 374 et al., 1999) . To mitigate this possibility several strategies will be employed in clinical trials. First, 375
CAR-IL18 T cells will be given in low doses where the calculated maximal levels of IL18 could not 376 reach the levels shown to be safe in humans in previous trials (Robertson et al., 2006) . Secondly, 377
if cytokine levels become a concern, they can be reduced by incorporation of various kill switch 378 strategies (Straathof et al., 2003) . Finally, a more elegant approach was developed here where 379 the IL18 transgene was not constitutively expressed, but rather, was only induced and secreted 380 upon encountering with the surrogate tumor antigen. Presumably this would limit IL18 secretion 381 to the tumor microenvironment, and limit systemic exposure. 382 A limitation of our in vivo studies is that they were conducted in an immunodeficient NSG 383 mouse model. A strength of this model is that it enabled testing of the APACHE CAR T cells in a 384 robust tumor model. However, the tumor microenvironment is lacking in this model since the 385 tumor stroma is composed largely of mouse cells. In humans and in mice, the biologic activity of 386 IL18 is balanced by the presence of a high affinity, naturally occurring IL18 binding protein 387 (IL18BP). This binding occurs with a high affinity and has been reported to occur interspecies 388 between mouse and human IL18 (Aizawa et al., 1999) . It is possible that the toxicity observed in 389 the mice manifested by systemic inflammation, weight loss and death in some cases, was 390 exaggerated or underreported based on the relative balance of mouse IL18BP and the 391 transgenic IL18 secreted by the APACHE T cells. 392
In summary, we demonstrate that CAR T cells can be engineered to secrete IL18 that supports in 393 vivo engraftment and persistence of the CAR T cells. Our observations demonstrate that IL18 has 394 a previously unappreciated form of costimulation on human CD4+ T cells, and therefore these 395
IL18 expressing CD4 T cells can be categorized as synthetic T helper cell producing IL18 (sTH18). 396
These findings may have therapeutic implications because the CAR IL18 T cells can support the 397 proliferation of CD8 T cells, and because increasing evidence points to the importance of 398 adoptively transferred CD4+ T cells in antitumor effects (Hunder et al., 2008; Hung et al., 1998) . 399 Finally, CAR T cells with inducible IL18 may have a role in immune-surveillance and have a 400 therapeutic potential for inducing antigenic spread. Before translation of this technology into 401 clinical setting, further investigation is underway to address the IL18-CART toxicity and biology in 402 syngeneic models . 403 linker (pTRPE SS1BBz-T2A-hIL18). GFP and Humanized CAR CD19BBz were cloned to replace 418
Materials and Methods
SS1BBz to generate pTRPE CD19BBz-T2A-hIL18 and pTRPE GFP-T2A-hIL18. GFP was cloned to 419 replace SS1BBz to generate pTRPE GFP. GFP was also cloned to replace hIL18 to generate pTRPE 420
SS1BBz-T2A-GFP and pTRPE CD19BBz-T2A-GFP. In order to generate the lentivector construct 421 pTRPE NFAT CD19-GFP-IL18, the parental vector pTRPE SS1BBz was depleted of the fragment 422 consisting EF1A promoter and SS1 BBz, and inserted with a reverse sequence of synthesized 423 fragment consisting of an NFAT promoter (Zhang et al., 2015) followed by GFP with a P2A (Kim 424 et al., 2011) linker. The resulting pTRPE NFAT GFP vector was modified by replacing GFP with 425
CD19BBz, which was further modified by inserting a fragment of GFP or GFP-T2A-IL18 426 downstream of P2A site to generate pTRPE NFAT CD19-GFP or CD19-GFP-IL18. 427 428
Primary T cell expansion 429
Primary donor T cells were transduced with lentivector encoding CAR or GFP with or without 430 hIL18 and expanded as previously reported (Milone et al., 2009 ). In brief, primary donor T cells 431
were activated with anti-CD3/CD28 Dynabeads (LifeTechnologies) at D0, and transduced with 432 lentivector at D1. Fresh medium was added at D3 and the activated T cells were de-beaded at 433 D5 and maintained at 7e5/ml until rested T cells were frozen in liquid nitrogen. with anti-CD3/CD28 Dynabeads (LifeTechnologies) at D0, and transduced with lentivector at D1. 440
The activated T cells were de-beaded at D3 and electroporated with sgRNA and Cas9 RNA at D3 441 and D4. Then the T cells were maintained at 7e5/ml until rested T cells were frozen in liquid 442 nitrogen. 443 444
TCR-deficient T cells were achieved with sgRNA targeting GGAGAATGACGAGTGGACCC within 445 TCRB region. For the IL18R knockout we designed 7 sgRNA targeting IL18RA (Cong et al., 2013; 446 Jinek et al., 2012; Mali et al., 2013) , and utilized RNA electroporation to induce CRISPR/Cas9 447 mediated gene editing following the procedure of generating TCR KO universal CART (Ren et al., 448 2015) . The screening of IL18RA KO showed that a the A4 sgRNA produced the most efficient 449 gene knockout (Figure 4-figure supplement 1A) , and sequencing of the PCR product spanning 450 the gene edited site confirmed mutations in the DNA sequence (GTACAAAAGCAGTGGATCAC) 451 targeted by the A4 sgRNA (Figure 4-figure supplement 1B CART cells demonstrated T cell infiltration and GVHD (see also Table S1 ). All data with error bars 669 are presented as mean±SEM. 670
The following figure supplements are available for figure 1: then electroporated with sgRNA targeting TCRB or IL18RA, and Cas9 RNA as described in 754
Methods. Three days after electroporation, T cells were stained with anti-CD3 or anti-IL18RA to 755 confirm gene knockout. T cells with TCR or IL18R knockout were stained with anti-CD3, or anti-756 IL18RA microbeads and negatively sorted by MACS. 
